MashupMD

Mashup Score: 31

AUA 2025: Cost-Effectiveness of Nivolumab or Pembrolizumab Versus Surveillance for the Adjuvant Treatment of Patients with High-Risk Muscle Invasive Bladder Cancer - 7 day(s) ago

AUA 2025, Muscle Invasive Bladder Cancer (MIBC), Nivolumab, Pembrolizumab, Cost-Effectiveness of Nivolumab or Pembrolizumab Versus Surveillance for the Adjuvant Treatment of Patients with High-Risk Muscle Invasive Bladder Cancer, AMBASSADOR study.

Source: www.urotoday.com

Categories: General Medicine News, General News

Tweet Tweets with this article
- urotoday
  
  Cost-effectiveness of nivolumab or pembrolizumab vs surveillance for the adjuvant treatment of patients with high-risk #MIBC. Presented by @PKanaburMD @UclaUrology. #AUA25 written coverage by @chavarriagaj @UofT > https://t.co/wbAXjKhH28 @AmerUrological https://t.co/6yylnWq3UJ